-
1
-
-
0037449586
-
Medicine: What are the right targets for psychopharmacology?
-
DOI 10.1126/science.1077141
-
Hyman SE, Fenton WS. Medicine. What are the right targets for psychopharmacology? Science. 2003;299:350-351. (Pubitemid 36120025)
-
(2003)
Science
, vol.299
, Issue.5605
, pp. 350-351
-
-
Hyman, S.E.1
Fenton, W.S.2
-
2
-
-
33645226430
-
The NIMH-MATRICS consensus statement on negative symptoms
-
Kirkpatrick B, Fenton WS, Carpenter WT, Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214-219.
-
(2006)
Schizophr Bull.
, vol.32
, pp. 214-219
-
-
Kirkpatrick, B.1
Fenton, W.S.2
Carpenter Jr., W.T.3
Marder, S.R.4
-
3
-
-
48949099564
-
Initial phase 2 trial of a nicotinic agonist in schizophrenia
-
Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry. 2008;165:1040-1047.
-
(2008)
Am. J. Psychiatry
, vol.165
, pp. 1040-1047
-
-
Freedman, R.1
Olincy, A.2
Buchanan, R.W.3
-
4
-
-
79952127537
-
Evaluation of the effects of AL-108 on neurocognition in schizophrenia: Initial TURNS study results
-
Hollywood, FL 7 December
-
Javitt DC, Buchanan RW, Lieberman JA, Keefe RS, Marder SR. Evaluation of the effects of AL-108 on neurocognition in schizophrenia: initial TURNS study results. Annual Meeting, American College of Neuropsychopharmacology. Hollywood, FL 7 December, 2009.
-
(2009)
Annual Meeting, American College of Neuropsychopharmacology
-
-
Javitt, D.C.1
Buchanan, R.W.2
Lieberman, J.A.3
Keefe, R.S.4
Marder, S.R.5
-
5
-
-
40949145164
-
Functional co-primary measures for clinical trials in schizophrenia: Results from the MATRICS Psychometric and Standardization Study
-
DOI 10.1176/appi.ajp.2007.07010089
-
Green MF, Nuechterlein KH, Kern RS, et al. Functional coprimary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry. 2008;165:221-228. (Pubitemid 351704522)
-
(2008)
American Journal of Psychiatry
, vol.165
, Issue.2
, pp. 221-228
-
-
Green, M.F.1
Nuechterlein, K.H.2
Kern, R.S.3
Baade, L.E.4
Fenton, W.S.5
Gold, J.M.6
Keefe, R.S.E.7
Mesholam-Gately, R.8
Seidman, L.J.9
Stover, E.10
Marder, S.R.11
-
6
-
-
20844439028
-
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia
-
DOI 10.1093/schbul/sbi020
-
Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005;31:5-19. (Pubitemid 41214353)
-
(2005)
Schizophrenia Bulletin
, vol.31
, Issue.1
, pp. 5-19
-
-
Buchanan, R.W.1
Davis, M.2
Goff, D.3
Green, M.F.4
Keefe, R.S.E.5
Leon, A.C.6
Nuechterlein, K.H.7
Laughren, T.8
Levin, R.9
Stover, E.10
Fenton, W.11
Marder, S.R.12
-
8
-
-
21844469260
-
Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers
-
DOI 10.1016/j.schres.2004.12.019, PII S092099640500006X
-
Barch DM, Carter CS. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res. 2005;77:43-58. (Pubitemid 40957060)
-
(2005)
Schizophrenia Research
, vol.77
, Issue.1
, pp. 43-58
-
-
Barch, D.M.1
Carter, C.S.2
-
9
-
-
78650158555
-
Toward new approaches to psychotic disorders: The NIMH research domain criteria project
-
Cuthbert BN, Insel TR. Toward new approaches to psychotic disorders: the NIMH Research Domain Criteria project. Schizophr Bull. 2010;36:1061-1062.
-
(2010)
Schizophr Bull.
, vol.36
, pp. 1061-1062
-
-
Cuthbert, B.N.1
Insel, T.R.2
|